Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH).However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, aluminum lotion side effects, or sociocultural factors.Selexipag is a recently approved prostacyclin receptor agonist that